Published in Int J Endocrinol on February 23, 2010
Is obstructive sleep apnea associated with cortisol levels? A systematic review of the research evidence. Sleep Med Rev (2011) 0.93
Sleep and obesity: a focus on animal models. Neurosci Biobehav Rev (2012) 0.93
Predictors of continuous positive airway pressure adherence. F1000 Med Rep (2010) 0.84
Impact of sleep respiratory disorders on endothelial function in children. ScientificWorldJournal (2013) 0.79
Sleep: important considerations for the prevention of cardiovascular disease. Curr Opin Cardiol (2016) 0.79
Obstructive sleep apnea and neurocognitive performance: the role of cortisol. Sleep Med (2013) 0.78
Incidence of hypothyroidism and its correlation with polysomnography findings in obstructive sleep apnea. Eur Arch Otorhinolaryngol (2014) 0.78
Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab (2010) 0.78
IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea. J Clin Sleep Med (2016) 0.75
Stress: aspects of endocrine hypertension. Dtsch Arztebl Int (2012) 0.75
Long-term compliance with continuous positive airway pressure in Saudi patients with obstructive sleep apnea. A prospective cohort study. Saudi Med J (2015) 0.75
Neonatal Maternal Separation Augments Carotid Body Response to Hypoxia in Adult Males but Not Female Rats. Front Physiol (2016) 0.75
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med (2000) 18.12
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Impact of sleep debt on metabolic and endocrine function. Lancet (1999) 14.89
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 14.25
Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med (2007) 8.25
Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol (1985) (2005) 6.47
Obstructive sleep apnoea. Lancet (2002) 6.37
Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med (2001) 5.94
Excess weight and sleep-disordered breathing. J Appl Physiol (1985) (2005) 4.72
Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med (1998) 4.65
Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab (2000) 4.34
Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab (1998) 3.75
Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ (2000) 3.60
The kidney, hypertension, and obesity. Hypertension (2003) 2.79
Upper airway surgery does not have a major role in the treatment of sleep apnea. Con. J Clin Sleep Med (2005) 2.48
On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab (2005) 2.25
Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax (1992) 2.21
Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med (1979) 2.21
Practice parameters for the use of portable monitoring devices in the investigation of suspected obstructive sleep apnea in adults. Sleep (2003) 2.21
Sleep apnea and sleep disruption in obese patients. Arch Intern Med (1994) 1.98
Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med (1996) 1.93
Effect of weight loss on upper airway collapsibility in obstructive sleep apnea. Am Rev Respir Dis (1991) 1.89
Abdominal fat and sleep apnea: the chicken or the egg? Diabetes Care (2008) 1.83
Association of serum leptin with hypoventilation in human obesity. Thorax (2002) 1.79
Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med (2003) 1.78
Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters. J Endocrinol Invest (2003) 1.71
The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration (2004) 1.63
Hormone replacement therapy and sleep-disordered breathing. Am J Respir Crit Care Med (2003) 1.61
The relationship between sleep apnea syndrome and hypothyroidism. Chest (1992) 1.57
Microarousals during sleep are associated with increased levels of lipids, cortisol, and blood pressure. Psychosom Med (2004) 1.51
Obstructive sleep apnoea and depression--diagnostic and treatment implications. Aust N Z J Psychiatry (1992) 1.48
Upper airway obstruction in hypothyroidism. J Intern Med (1994) 1.48
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol (Oxf) (1999) 1.48
Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J (2003) 1.41
Ventilatory control in myxedema and hypothyroidism. N Engl J Med (1975) 1.36
Human growth hormone release during sleep: electroencephalographic correlation. J Clin Endocrinol Metab (1969) 1.35
Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol (1985) (2002) 1.35
Hypothalamic-pituitary dysfunction in respiratory hypoxia. Thorax (1981) 1.30
Sleep-disordered breathing and nocturnal oxygen desaturation in postmenopausal women. Am J Med (1980) 1.29
Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. J Clin Endocrinol Metab (1989) 1.25
Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas (2001) 1.22
Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension (2004) 1.22
Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am (2003) 1.22
Hypothalamic-pituitary-adrenal axis activity in obese men with and without sleep apnea: effects of continuous positive airway pressure therapy. J Clin Endocrinol Metab (2007) 1.16
Impact of menopause on the prevalence and severity of sleep apnea. Chest (2001) 1.16
Pathophysiological mechanisms in obstructive sleep apnea. Sleep (1980) 1.16
Pathogenesis and pathophysiology of the obstructive sleep apnea syndrome. Med Clin North Am (1985) 1.15
Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med (2004) 1.12
The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab (2003) 1.12
Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) (2006) 1.11
Plasma angiotensinogen concentrations in obese patients. Am J Hypertens (1997) 1.11
Acute withdrawal of nasal CPAP in obstructive sleep apnea does not cause a rise in stress hormones. Sleep (1996) 1.09
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. Respiration (2005) 1.09
Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab (2002) 1.08
Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. J Intern Med (2003) 1.07
Vasopressin, ACTH, and corticosteroids during hypercapnia and graded hypoxia in dogs. Am J Physiol (1983) 1.05
Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. Intern Med (2008) 1.04
Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med (1983) 1.02
Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables. Clin Endocrinol (Oxf) (2003) 1.01
Pituitary reactivity, androgens and catecholamines in obstructive sleep apnoea. Effects of continuous positive airway pressure treatment (CPAP). Respir Med (1999) 1.01
Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) (1985) 0.99
Association between sleep and morning testosterone levels in older men. Sleep (2007) 0.98
Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res (2004) 0.97
Low level of IGF-1 in obesity may be related to obstructive sleep apnea syndrome. Lung (2007) 0.96
Obstructive sleep apnea syndrome is a systemic disease. Current evidence. Eur J Intern Med (2008) 0.96
Myxedema and obstructive sleep apnea. Am J Med (1981) 0.95
Altered luteinizing hormone and testosterone secretion in middle-aged obese men with obstructive sleep apnea. Obes Res (2005) 0.95
Contemporary surgery for obstructive sleep apnea syndrome. Clin Exp Otorhinolaryngol (2009) 0.93
Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men. J Clin Endocrinol Metab (2001) 0.93
Interactions between obstructive sleep apnea and the metabolic syndrome. Curr Diab Rep (2005) 0.92
Continuous positive airway pressure therapy decreases evening cortisol concentrations in patients with severe obstructive sleep apnea. Metabolism (2009) 0.92
Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration (2005) 0.92
Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. J Endocrinol (1998) 0.91
Association of hypothyroidism and obstructive sleep apnea. Am J Respir Crit Care Med (1998) 0.90
Influence of testosterone on breathing during sleep. J Appl Physiol (1985) (1986) 0.90
Insulin suppresses growth hormone secretion by rat pituitary cells. J Clin Invest (1984) 0.90
Sleep apnea and hypothyroidism: mechanisms and management. Am J Med (1988) 0.89
Effect of continuous positive airway pressure therapy on hypothalamic-pituitary-adrenal axis function and 24-h blood pressure profile in obese men with obstructive sleep apnea syndrome. Am J Physiol Endocrinol Metab (2008) 0.89
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine (2001) 0.89
The renin-angiotensin-aldosterone system in patients with depression compared to controls--a sleep endocrine study. BMC Psychiatry (2003) 0.88
Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension (1982) 0.88
Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men. Am J Physiol Endocrinol Metab (2007) 0.88
Obese patients with obstructive sleep apnoea syndrome show a peculiar alteration of the corticotroph but not of the thyrotroph and lactotroph function. Clin Endocrinol (Oxf) (2004) 0.88
Adiponectin in patients with obstructive sleep apnea syndrome: course and physiological relevance. Respiration (2005) 0.88
Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. J Clin Endocrinol Metab (2002) 0.87
Sleep-disordered breathing and hormones. Eur Respir J (2003) 0.86
Continuous positive airway pressure treatment. Effects on growth hormone, insulin and glucose profiles in obstructive sleep apnea patients. Horm Metab Res (1993) 0.86
Reversible reproductive dysfunction in men with obstructive sleep apnoea. Clin Endocrinol (Oxf) (1988) 0.86
Renin-angiotensin-aldosterone system and physical exercise. J Sports Med Phys Fitness (1993) 0.86
Total but not bioavailable testosterone is a predictor of central adiposity in postmenopausal women. Int J Obes Relat Metab Disord (1995) 0.85
Serum concentrations of total T4, T3, reverse T3 and free T4, T3 in moderately obese patients. Hum Nutr Clin Nutr (1985) 0.85
ACTH and cortisol responses to hypoxia in dogs. J Appl Physiol Respir Environ Exerc Physiol (1981) 0.84
Lung volume-related changes in the pharyngeal area of obese females with and without obstructive sleep apnoea. Eur Respir J (1989) 0.84
Disordered growth hormone and prolactin secretion in primary disorders of sleep. Neurology (1979) 0.84
Leptin, obesity, and obstructive sleep apnea. Chest (2000) 0.83
Adrenal and gonadal function in obesity. J Endocrinol Invest (2002) 0.83
Screening for hypothyroidism in sleep apnea. Am J Respir Crit Care Med (1999) 0.83
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension (2006) 4.20
Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev (2004) 3.79
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Hypopituitarism. Lancet (2007) 2.27
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol (2002) 1.97
Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension (2013) 1.76
Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA (2007) 1.59
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol (2005) 1.59
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Endocrine function is altered in chronic migraine patients with medication-overuse. Headache (2006) 1.47
The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens (2010) 1.46
Role of sleep duration in the regulation of glucose metabolism and appetite. Best Pract Res Clin Endocrinol Metab (2010) 1.46
Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension (2009) 1.45
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab (2002) 1.45
Technology and instrumentation for detection and conditioning of the surface electromyographic signal: state of the art. Clin Biomech (Bristol, Avon) (2008) 1.39
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab (2004) 1.39
Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab (2008) 1.38
Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J (2004) 1.32
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine (2012) 1.32
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res (2009) 1.26
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab (2012) 1.24
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol (2002) 1.24
Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes (2007) 1.22
Experimental analysis of accuracy in the identification of motor unit spike trains from high-density surface EMG. IEEE Trans Neural Syst Rehabil Eng (2010) 1.18
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension (2007) 1.13
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab (2003) 1.12
Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab (2002) 1.11
Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol (2010) 1.09
Atlas of the muscle motor points for the lower limb: implications for electrical stimulation procedures and electrode positioning. Eur J Appl Physiol (2011) 1.06
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab (2007) 1.06
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol (2004) 1.05
Effect of food restriction on ghrelin in normal-cycling female rats and in pregnancy. Obes Res (2002) 1.04
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis (2005) 1.03
Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood) (2011) 1.02
The IGF system. Acta Diabetol (2010) 1.01
Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol (2004) 1.01
Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables. Clin Endocrinol (Oxf) (2003) 1.01
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. Eur J Endocrinol (2009) 1.00
Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Mol Cell Endocrinol (2006) 0.99
Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol (2003) 0.98
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. Clin Endocrinol (Oxf) (2003) 0.97
Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens (2007) 0.96
Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells. Endocrinology (2008) 0.96
Endocrine and metabolic responses to extreme altitude and physical exercise in climbers. Eur J Endocrinol (2007) 0.95
Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab (2006) 0.95
Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes (2010) 0.95
Ghrelin secretion in childhood is refractory to the inhibitory effect of feeding. J Clin Endocrinol Metab (2004) 0.95
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol (2007) 0.94
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab (2014) 0.94
The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology (2002) 0.93
Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) (2011) 0.93
Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol (2014) 0.92
Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology (2007) 0.92
Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab (2012) 0.92
Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology (2007) 0.92
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans. Clin Endocrinol (Oxf) (2004) 0.92
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol (2009) 0.91
Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J (2012) 0.91
Association of craniopharyngioma and pituitary adenoma. Endocrine (2013) 0.88
Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab (2002) 0.88
Ghrelin drives GH secretion during fasting in man. Eur J Endocrinol (2002) 0.88
Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol (2010) 0.88
GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology (2013) 0.88
Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. J Clin Endocrinol Metab (2008) 0.87
Corticotrope hypersecretion coupled with cortisol hypo-responsiveness to stimuli is present in patients with autoimmune endocrine diseases: evidence for subclinical primary hypoadrenalism? Eur J Endocrinol (2006) 0.87
Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. Endocrinology (2002) 0.87
Varicocele sclerotherapy improves serum inhibin B levels and seminal parameters. Int J Androl (2007) 0.87
A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res Ther (2008) 0.87
Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. Eur J Endocrinol (2009) 0.87
Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. Am J Pathol (2003) 0.87
Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome. Pituitary (2004) 0.87
Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. Eur J Endocrinol (2010) 0.86
Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) (2006) 0.86
Detection of antipituitary and antihypothalamus antibodies to investigate the role of pituitary or hypothalamic autoimmunity in patients with selective idiopathic hypopituitarism. Clin Endocrinol (Oxf) (2011) 0.86
Unacylated ghrelin promotes skeletal muscle regeneration following hindlimb ischemia via SOD-2-mediated miR-221/222 expression. J Am Heart Assoc (2013) 0.86
The nutritional control of ghrelin secretion in humans: the effects of enteral vs. parenteral nutrition. Eur J Nutr (2006) 0.86
Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol (2005) 0.86